Full Text:
<2734>
CLC number: R394
On-line Access:
Received: 2005-11-22
Revision Accepted: 2006-01-18
Crosschecked: 0000-00-00
Cited: 7
Clicked: 5404
Pharmacogenetics, pharmacogenomics and ecogenetics
| |||||||||||||
Motulsky Arno G., Qi Ming. Pharmacogenetics, pharmacogenomics and ecogenetics[J]. Journal of Zhejiang University Science B, 2006, 7(2): 169-170.
@article{title="Pharmacogenetics, pharmacogenomics and ecogenetics",
author="Motulsky Arno G., Qi Ming",
journal="Journal of Zhejiang University Science B",
volume="7",
number="2",
pages="169-170",
year="2006",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.2006.B0169"
}
%0 Journal Article
%T Pharmacogenetics, pharmacogenomics and ecogenetics
%A Motulsky Arno G.
%A Qi Ming
%J Journal of Zhejiang University SCIENCE B
%V 7
%N 2
%P 169-170
%@ 1673-1581
%D 2006
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.2006.B0169
TY - JOUR
T1 - Pharmacogenetics, pharmacogenomics and ecogenetics
A1 - Motulsky Arno G.
A1 - Qi Ming
J0 - Journal of Zhejiang University Science B
VL - 7
IS - 2
SP - 169
EP - 170
%@ 1673-1581
Y1 - 2006
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.2006.B0169
Abstract: pharmacogenetics and pharmacogenomics deal with the role of genetic factors in drug effectiveness and adverse drug reactions. The promise of a personalized medicine is beginning to be explored but requires much more clinical and translational research. Specific DNA abnormalities in some cancers already have led to effective targeted treatments. Racially determined frequency differences in pharmacogenetic traits may affect choice of treatment requiring specific testing rather than basing treatments according to racial designation. The role of genes in variable responses to foreign chemicals (xenobiotics) has been termed ecogenetics or toxicogenetics raising problems in public health and occupational medicine. nutrigenetics refers to genetic variation in response to nutrients and may affect nutritional requirements and predisposition to chronic disease.
[1] Andrawiss, M., 2005. First phase of HapMap project already helping drug discovery. Nature Reviews. Drug Discovery, 4(12):947.
[2] Couzin, J., 2004. Pharmacogenomics: cancer sharpshooters rely on DNA tests for a better aim. Science, 305(5688):1222a-1223a.
[3] Motulsky, A.G., 1957. Drug reactions, enzymes and biochemical genetics. Journal of the American Medical Association, 165:835-837.
[4] Motulsky, A.G., 1987. human genetic variation and nutrition. American Journal of Clinical Nutrition, 45:1108-1113.
[5] Motulsky, A.G., 2002. from pharmacogenetics and ecogenetics to pharmacogenomics. Medicina nei Secoli Arte e Scienza (Journal of history of Medicine), 14:683-705.
[6] Nebert, D.W., Jorge-Nebert, L., Vesell, E.S., 2003. pharmacogenomics and “individualized drug therapy”: high expectations and disappointing achievements. American Journal of Pharmacogenomics, 3:361-370.
[7] Need, A.C., Motulsky, A.G., Goldstein, D.B., 2005. priorities and standards in pharmacogenetic research. Nature Genetics, 37(7):671-681.
[8] Tate, S.K., Goldstein, D.B., 2004. Will tomorrow’s medicines work for everyone? Nature Genetics, 36(11s):S34-S42.
[9] Vesell, E.S., Page, J.G., 1968. Genetic control of drug levels in man: phenylbutazone. Science, 159:1479-1480.
[10] Vogel, F., 1959. Moderne problem der humangenetik. Ergeb. Inn. Med. U. Kinderheilk, 12:52-125.
[11] Weinshilboum, R., 2003. Inheritance and drug response. New England Journal of Medicine, 348(6):529-537.
Open peer comments: Debate/Discuss/Question/Opinion
<1>